Data Intuitive comparison, vs nf-core, vs Terra, vs DNAnexus, vs Latch, vs Seven Bridges, build vs buy bioinformatics, Multi-omics platform alternatives, Bioinformatics platform comparison, Validated pipelines, Nextflow, Viash, Customer-owned compute, Audit-ready
We won't pretend to be the right answer for every team. Here's how we compare to the alternatives, and when one of them is the better choice.
Validated pipelines, customer-owned compute, audit-ready outputs and PhD-level scientific support, packaged as one product. We're commercial-grade, not a research framework, and we sit in your environment, not ours.
For each alternative: when it's the better fit, and when we are.
Open-source, community-maintained Nextflow pipelines.
Choose nf-coreif you have a strong and stable bioinformatics team, a working deployment with no changes needed, and no need for audit trails, validation packages or expert support.
Choose usif you want the same Nextflow rigour with a validated catalogue and one accountable vendor. We build on the same open-source foundations, so you don't depend on a single team to keep it running.
Cloud-native platform on Google Cloud, by the Broad Institute.
Choose Terraif your team is fluent in WDL and stable enough to maintain it. Strong academic and consortium fit, especially for genomics.
Choose usif you need one platform across AWS, Azure, GCP and on-prem, and you work in multi-omics, not just genomics.
Cloud-based platform with strong clinical and regulatory focus.
Choose DNAnexusif your primary work is GxP-grade clinical bioinformatics and FDA submissions. They have deeper history in that exact lane.
Choose usif you're upstream of clinical: R&D, target discovery, biomarker work. Our modular catalogue makes reuse easy. Audit-ready without paying for clinical infrastructure you don't need.
Modern commercial bioinformatics platforms.
Choose themif you want a hosted platform model with a US vendor relationship. Good fits for specific workflows already in their catalogue.
Choose usif you need European data residency as an infrastructure option, customer-owned compute, open-source foundations (Viash, Nextflow), or a partner that ships PhD-level scientific support alongside the platform.
Your bioinformatics team builds and maintains everything in-house.
Buildif you have a mature, stable bioinformatics team with the headcount to maintain pipelines, audit trails and infrastructure as a permanent investment.
Buy usif your bioinformaticians should be doing the interesting bioinformatics work, governed, not plumbed. We take the catalogue, the audit and the infrastructure off their plate so they can ship science.
Indicative market positioning based on public knowledge (January 2026). Intended as a discussion and evaluation aid, not as a formal benchmark. For a real vendor shortlist, each cell should be verified with the supplier itself.
| Criterion | Data Intuitive | DNAnexus | VelseraSeven Bridges | IlluminaConnected Analytics | BenchlingInsights | TerraBroad | SeqeraNextflow Tower | In-house build |
|---|---|---|---|---|---|---|---|---|
| Data stays in customer environment | ✓ | ~ | ~ | ✗ | ✗ | ~ | ✓ | ✓ |
| Vendor-neutral (kit / instrument) | ✓ | ✓ | ✓ | ✗ | ~ | ✓ | ✓ | ✓ |
| Multi-omics (bulk, sc, spatial, MS) | ✓ | ~ | ~ | ~ | ~ | ✓ | ~ | ~ |
| Validated pipeline catalogue | ✓ | ✓ | ✓ | ✓ | ~ | ~ | ✗ | ✗ |
| R&D audit trail / ISO 27001Platform default | ✓ | ✓ | ✓ | ✓ | ✓ | ~ | ~ | ✗ |
| GAMP 5 / 21 CFR Part 11Enterprise service | ~ | ✓ | ✓ | ✓ | ~ | ✗ | ~ | ~ |
| ISO 13485 alignmentEnterprise scope | ~ | ~ | ~ | ✓ | ✗ | ✗ | ✗ | ✗ |
| Open-source foundation | ✓Viash | ~WDL | ~CWL | ✗ | ✗ | ✓ | ✓Nextflow | – |
| Keep-forever / exit licence | ✓ | ✗ | ✗ | ✗ | ✗ | – | ~ | – |
| On-prem / air-gapped deploy | ✓ | ~ | ~ | ✗ | ✗ | ✗ | ✓ | ✓ |
| HPC support | ✓ | ~ | ~ | ✗ | ✗ | ✗ | ✓ | ✓ |
| Multi-cloud (AWS / GCP / Azure) | ✓ | ✓ | ✓ | ~ | ~ | ~GCP | ✓ | ~ |
| Browser-based self-service | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ~ |
| Pay-as-you-go credits | ✓ | ✓ | ✓ | ✓ | ✗ | ~ | ~ | ✗ |
| OEM / white-label option | ✓ | ~ | ~ | ✗ | ✗ | ✗ | ~ | – |
| LIMS integration | ✓ | ✓ | ✓ | ✓ | ✓ | ~ | ~ | ~ |
| PhD-staffed services arm | ✓ | ~ | ✓ | ~ | ~ | ✗ | ~ | ✗ |
| Training programme (academy) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✗ |
| EU data residency / sovereign | ✓ | ~ | ~ | ~ | ~ | ✗ | ~ | ✓ |
| Compute-independent billingNo markup on cloud | ✓ | ~ | ~ | ✗ | – | ✓ | ✓ | ✓ |
| Scale / enterprise references | ~ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | – |
| Financial scale / continuity risk low | ~ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | – |
| Lock-in risk (lower is better) | ✓Low | ~Medium | ~Medium | ✗High | ✗High | ~Medium | ✓Low | ✓Low |
The Data Intuitive profile stands out on three rare ✓ combinations that are usually ✗ or ~ elsewhere: data stays in the customer environment, a keep-forever exit licence, and an open-source foundation (Viash) underneath the commercial platform. That is precisely the quadrant that an R&D-IT or compliance team values when lock-in and data sovereignty are the primary risks.
The two weaker spots in the same table are also clear: scale / enterprise references and financial continuity score ~ because the company is small and European. That is not a technical shortfall but a procurement risk, partly mitigated by the keep-forever clause and ISO 27001, and worth a separate due-diligence pass.
Against Illumina Connected Analytics and Benchling Insights, Data Intuitive positions explicitly on the other side of the spectrum: less ecosystem lock-in, more architectural freedom. Against Seqera / Nextflow Tower it shares the open-source philosophy but adds a validated catalogue and services arm that Seqera does not carry as a core proposition. Against DNAnexus and Velsera it competes on vendor neutrality, sovereignty and the exit clause, not on scale or pharma-installed base.
30 minutes to compare against your real constraints. If we're not the right fit, we'll say so and point you to who is.
Book a scoping call